Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04314284
Other study ID # 202003033
Secondary ID 1P50CA244431-01
Status Completed
Phase N/A
First received
Last updated
Start date May 26, 2020
Est. completion date November 4, 2021

Study information

Verified date May 2023
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to incorporate feedback from cancer patients and providers to adapt, implement, and test an intervention. The intervention aims to prompt screening for financial distress, facilitate discussions about care costs with cancer patients, support health insurance selection, and ultimately reduce cancer patients' financial toxicity associated with cancer care.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date November 4, 2021
Est. primary completion date August 27, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Eligibility criteria for I Can Pic Arm only: Inclusion Criteria: - 18 years of age or older - Must have been diagnosed with colorectal cancer, lung cancer, or gynecologic cancer < 5 months ago and be patients of one of the 15 providers - This cancer diagnosis must be the first and primary diagnosis Exclusion Criteria: - Not able to read and understand English - Cannot give informed consent due to cognitive or emotional barriers

Study Design


Intervention

Behavioral:
I Can PIC
-Online decision tool that explains health insurance terms and health insurance terms, provides tips on lowering health care costs, advises patient to discuss costs with provider and insurance, and provides financial resources for patient.
Other:
Historical control survey
-31 questions including overall experience with cancer care provider, previous discussions with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, confidence in health care choices and health insurance choices, current health conditions, and demographic data.
Post-intervention survey (I Can PIC participants)
-31 questions including overall experience with cancer care provider, previous discussions with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, confidence in health care choices and health insurance choices, current health conditions, and demographic data.
Follow-Up survey (I Can PIC participants)
-19 questions including overall experience with cancer care provider, discussion with care team regarding health care costs, preferences for discussing health care costs with physician, confidence level on discussing health care costs with physician, feelings about current financial situation, delays or avoidance of medical care in the past 12 months, and confidence in health care choices and health insurance choices.

Locations

Country Name City State
United States Washington University School of Medicine Saint Louis Missouri

Sponsors (2)

Lead Sponsor Collaborator
Washington University School of Medicine National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Delayed or Forgone Care Due to Costs (I Can PIC Arm) Delayed or forgone care due to costs will be collected on the post-intervention survey and the 3-6 month follow-up survey
Score from 0 (best) to 8 (worst). Higher scores indicate more frequent delayed and forgone care due to costs
Change from post-intervention survey to 3-6 month follow-up survey (estimated to be a total of 6 months)
Other Delayed or Forgone Care Due to Costs (Historical Control Arm and I Can PIC Arm) Delayed or forgone care due to costs will be collected on the historical control survey and the I Can PIC post-intervention survey
Score from 0 (best) to 8 (worst). Higher scores indicate more frequent delayed and forgone care due to costs
Completion of survey (estimated to be approximately 1-14 days after enrollment)
Primary Difference in Health Insurance Knowledge Between Historical Control Arm and I Can PIC Arm Health insurance knowledge will be collected on the historical control survey and the I Can PIC post-intervention survey
Score from 0% (worst) to 100% (best). Higher scores indicate greater health insurance knowledge
Completion of survey (estimated to be approximately 1-14 days after enrollment)
Primary Difference in Health Insurance Literacy Between Historical Control Arm and I Can PIC Arm Health insurance literacy will be collected on the historical control survey and the I Can PIC post-intervention survey
Score from 12 (worst) to 48 (best). Higher scores indicate greater health insurance literacy
Completion of survey (estimated to be approximately 1-14 days after enrollment)
Primary Difference in the Number of Clinicians That Discussed Health Care Cost Topics With Participants Between the Historical Control Arm and I Can PIC Arm Information regarding clinicians who discussed health care costs will be collected on the historical control survey and the I Can PIC post-intervention survey
Score either no (did not discuss health care costs with clinician) or yes (discussed one more cost-related topics with clinicians)
Also score the number of cost-related topics discussed, if yes
Completion of survey (estimated to be approximately 1-14 days after enrollment)
Primary Difference in the Number of Cost-related Topics Discussed With Participants Between the Historical Control Arm and I Can PIC Arm -Information regarding clinicians who discussed health care costs will be collected on the historical control survey and the I Can PIC post-intervention survey Completion of survey (estimated to be approximately 1-14 days after enrollment)
Primary Difference in the Number of Clinicians That Discussed Health Care Cost Strategies Between the Historical Control Arm and I Can PIC Arm -Information regarding clinicians who discussed health care costs will be collected on the historical control survey and the I Can PIC post-intervention survey Completion of survey (estimated to be approximately 1-14 days after enrollment)
Primary Difference in the Number of Cost Strategies Discussed Between the Historical Control Arm and I Can PIC Arm -Information regarding clinicians who discussed health care costs will be collected on the historical control survey and the I Can PIC post-intervention survey Completion of survey (estimated to be approximately 1-14 days after enrollment)
Primary Difference in Confidence Communicating About Health Care Costs With Physician Between Historical Control Arm and I Can PIC Arm Confidence communicating about health care costs will be collected on the historical control survey and the I Can PIC post-intervention survey
Score from 4 (worst) to 16 (best). Higher scores indicate greater confidence communicating about care costs
Completion of survey (estimated to be approximately 1-14 days after enrollment)
Primary Difference in Financial Toxicity Between Historical Control Arm and I Can PIC Arm Financial toxicity will be collected on the historical control survey and the I Can PIC post-intervention survey
Score from 0 (best) to 44 (worst). Higher scores indicate greater financial toxicity
Completion of survey (estimated to be Day 1 for historical control participants and estimated to be Day 14 for I Can PIC participants)
Primary Difference in Number of Clinicians Who Referred Patients to Resources to Discuss Costs Information regarding clinicians who discussed health care costs will be collected on the historical control survey and the I Can PIC post-intervention survey
Score either no (did not refer to resources) or yes (referred to resources)
Also score the number of cost-related topics discussed, if yes
Completion of survey (estimated to be approximately 1-14 days after enrollment)]
Secondary Health Insurance Knowledge Sustained Over Time (I Can PIC Arm) Sustained Health insurance knowledge will be collected on the post-intervention survey and the 3-6 month follow-up survey
Score from 0% (worst) to 100% (best). Higher scores indicate greater health insurance knowledge
Change from post-intervention survey to 3-6 month follow-up survey (estimated to be a total of 6 months)
Secondary Health Insurance Literacy Sustained Over Time (I Can PIC Arm) Sustained Health insurance literacy will be collected on the post-intervention survey and the 3-6 month follow-up survey
Score from 12 (worst) to 48 (best). Higher scores indicate greater health insurance literacy
Change from post-intervention survey to 3-6 month follow-up survey (estimated to be a total of 6 months)
Secondary Confidence Communicating About Health Care Costs With Physician (I Can PIC Arm) Confidence communicating about health care costs will be collected on the post-intervention survey and the 3-6 month follow-up survey
Score from 4 (worst) to 16 (best). Higher scores indicate greater confidence communicating about care costs
Change from post-intervention survey to 3-6 month follow-up survey (estimated to be a total of 6 months)
Secondary Sustained Financial Toxicity (I Can PIC Arm) Sustained Financial toxicity will be collected on the post-intervention survey and the 3-6 month follow-up survey
Score from 0 (best) to 44 (worst). Higher scores indicate greater financial toxicity
Change from post-intervention survey to 3-6 month follow-up survey (estimated to be a total of 6 months)
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A